Piron Bénédicte, Costes-Tertrais Domitille, Gastinne Thomas, Fourmont Aude Marie, Dubruille Viviane, Blin Nicolas, Moreau Philippe, Touzeau Cyrille, Tessoulin Benoit
Department of Hematology, University Hospital, Nantes, France.
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Br J Haematol. 2024 Jan;204(1):186-190. doi: 10.1111/bjh.19148. Epub 2023 Oct 13.
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
关于蛋白酶体抑制剂、免疫调节药物、抗CD38单克隆抗体以及靶向B细胞成熟抗原（BCMA）的疗法均治疗失败的复发多发性骨髓瘤患者（四重暴露[QCE]）的预后数据非常稀少。在这项回顾性单中心研究中，我们确定了45例QCE患者抗BCMA治疗失败后的无进展生存期（PFS）和总生存期（OS）。7例（16%）患者接受了抗体药物偶联物治疗，20例（44%）接受了双特异性抗体治疗，18例（40%）接受了嵌合抗原受体T细胞（CAR-T）治疗。30例（67%）患者接受了≥1线后续治疗。PFS为4.4个月（95%置信区间[CI]=2.4-12.5），OS为6.3个月（95%CI=3.9-14.4）。QCE骨髓瘤患者预后不良，仍然存在未满足的医疗需求。
